Does ADMA cause endothelial dysfunction? Review uri icon

Overview

abstract

  • Asymmetric dimethylarginine (ADMA) is an endogenous and competitive inhibitor of nitric oxide synthase. Plasma levels of this inhibitor are elevated in patients with atherosclerosis and in those with risk factors for atherosclerosis. In these patients, plasma ADMA levels are correlated with the severity of endothelial dysfunction and atherosclerosis. By inhibiting the production of nitric oxide, ADMA may impair blood flow, accelerate atherogenesis, and interfere with angiogenesis. ADMA may be a novel risk factor for vascular disease.

publication date

  • September 1, 2000

Research

keywords

  • Amidohydrolases
  • Arginine
  • Arteriosclerosis
  • Endothelium, Vascular
  • Nitric Oxide

Identity

Scopus Document Identifier

  • 0033813512

PubMed ID

  • 10978245

Additional Document Info

volume

  • 20

issue

  • 9